Synthetic MHC class I peptide prolongs cardiac survival and attenuates transplant arteriosclerosis in the Lewis→Fischer 344 model of chronic allograft rejection

Transplantation

Volumn 64, Issue 1, 1997, Pages 14-19

  Murphy, Barbara ^a   Kim, Kyung S ^b   Buelow, Roland ^b   Sayegh, Mohamed H ^a   Hancock, Wayne W ^c,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b GENZYME CORPORATION   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; GAMMA INTERFERON; HLA B7 ANTIGEN; IMMUNOGLOBULIN G2; INTERLEUKIN 2 RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ALLOGRAFT; ANIMAL CELL; ANIMAL TISSUE; ARTERIOSCLEROSIS; ARTICLE; CONTROLLED STUDY; GRAFT REJECTION; HEART TRANSPLANTATION; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; LYMPHOCYTIC INFILTRATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ARTERIOSCLEROSIS; CHRONIC DISEASE; CYCLOSPORINE; DISEASE MODELS, ANIMAL; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HLA-B ANTIGENS; IMMUNOSUPPRESSIVE AGENTS; MALE; RATS; RATS, INBRED F344; RATS, INBRED LEW; TRANSPLANTATION, HOMOLOGOUS;

EID: 0030805065     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199707150-00004     Document Type: Article

References (26)

1. Carpenter CB. Long-term failure of renal transplants: adding insult to injury. Kidney Int 1995; 48: S40.
2. Hostetter TH. Chronic transplant rejection. Kidney Int 1994; 46: 266.
3. Paul LC, Fellstrom B. Chronic vascular rejection of the heart and kidney: have rational treatment options emerged? Transplantation 1992; 53: 1169.
4. Paul L. Chronic renal transplant loss. Kidney Int 1995; 47: 1491.
5. Adams DH, Russell WW, Hancock WW, Sayegh MH, Wyner LR, Karnovsky MJ. Chronic rejection in experimental cardiac transplantation: studies in the Lewis-F344 model. Immunol Rev 1993; 134: 7.
6. Russell ME, Fujita M, Masek MA, Rowan RA, Billingham ME. Cardiac graft vascular disease: nonselective involvement of large and small vessels. Transplantation 1993; 56: 1115.
7. Tullius SG, Tilney NL. Both alloantigen-dependent and -independent factors influence chronic allograft rejection. Transplantation 1995; 59: 313.
8. Sayegh MH, Krensky AM. Novel immunotherapeutic strategies using MHC derived peptides. Kidney Int 1996; 49: S13.
9. Murphy B, Sayegh M. Immunomodulatory function of MHC-derived peptides. Curr Opin Neph Hyper 1996; 5: 262.
10. Parham P, Clayberger C, Zorn SL, Ludwig DS, Schoolnik GK, Krensky AM. Inhibition of alloreactive cytotoxic T lymphocytes by peptides from the alpha-2 domain of HLA-A2. Nature 1987; 325: 625.
11. Clayberger C, Parham P, Rothbard J, Ludwig DS, Schoolnik GK, Krensky AM. HLA-A2 peptides can regulate cytolysis by human allogeneic T lymphocytes. Nature 1987; 330: 763.
12. Clayberger C, Lyu SC, Pouletty P, Krensky AM. Peptides corresponding to T cell receptor HLA contact regions inhibit class I restricted immune responses. Transplant Proc 1993; 25: 477.
13. Nisco S, Vriens P, Hoyt G, et al. Induction of allograft tolerance in rats by an HLA-class I derived peptide and cyclosporine A. J Immunol 1994; 152: 3786.
14. Buelow R, Veyron P, Clayberger C, Pouletty P, Touraine J-L. Prolongation of skin allograft survival in mice following administration of Allotrap. Transplantation 1995; 59: 455.
15. Cuturi M-C, Josien R, Douillard P, et al. Prolongation of allogeneic heart graft survival in rats by administration of a peptide (a.a. 75-84) from the α1 helix of the first domain of HLA-B7 01. Transplantation 1995; 59: 661.
16. Woo J, Gao L, Cornejo M-C, Buelow R. A synthetic dimeric HLA class I peptide inhibits T cell activity in vitro and prolongs allogeneic heart graft survival in a mouse model. Transplantation 1995; 60: 1156.
17. Hanaway MJ, Geissler EK, Wang J, Fechner JH, Buelow R, Knechtle SJ. Immunosuppressive effects of an HLA class I-derived peptide in a rat cardiac allograft model. Transplantation 1996; 61: 1222.
18. Russell ME, Adams DH, Wyner LR, Yamashita Y, Halnon NJ, Karnovsky MJ. Early and persistent induction of monocyte chemoattractant protein 1 in rat cardiac allografts. Proc Natl Acad Sci USA 1993; 90: 6086.
19. Russell ME, Hancock WW, Akalin E, et al. Chronic cardiac rejection in the LEW to F344 rat model: blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis. J Clin Invest 1996; 97: 833.
20. Hancock WW, Whitley WD, Tullius SG, et al. Cytokines, adhesion molecules and the pathogenesis of chronic rejection of renal allografts. Transplantation 1993; 56: 643.
21. Hancock WW, Adams DH, Wyner LR, Sayegh MH, Karnovesky MJ. CD4+ mononuclear cells induce cytokine expression, vascular smooth muscle cell proliferation and arterial occlusion after endothelial injury. Am J Pathol 1994; 145: 1008.
22. Azuma H, Chandraker A, Nadeau K, et al. Blockade of T cell costimulation prevents development of experimental chronic allograft rejection. Proc Natl Acad Sci USA 1996; 93: 12439.
23. Forbes RDC, Zheng S-X, Gomersall M, Al-Saffar M, Guttmann RD. Evidence that recipient CD8+ T cell depletion does not alter development of chronic vascular rejection in a rat heart allograft model. Transplantation 1994; 57: 1238.
24. Ferraresso M, Tian L, Ghobrial R, Stepkowski SM, Kahan BD. Rapamycin inhibits production of cytotoxic but not noncytotoxic antibodies and preferentially activates Th2 cells that mediate long-term survival of heart allografts in rats. J Immunol 1994; 153: 3307.
25. Bach FH, Ferran C, Mark W, Winkler H, Hancock WW. Accommodation of vascularized xenografts: expression of "protective genes" by donor endothelial cells in a host Th2 cytokine environment. Nature Med 1997; 3: 196.
26. Nobner E, Goldberg J, Lyu S-C, Naftzger C, Clayberger C, Krensky A. HLA-derived peptides which inhibit T cell function bind to members of the heat-shock protein 70 family. J Exp Med 1996; 183: 1.